Abstract
There are growing concerns that current treatments for r/r B-cell NHL and MM are increasing the incidence of SPMs. While on-going clinical trial data suggest that SPM incidence is within the expected range, available SPM incidence benchmarks are unstable due to small numbers. We estimated the incidence rates (IR) of SPMs in r/r B-cell NHL and MM using the Cancer Analysis System (CAS), a population-level cancer database in England for patients diagnosed from 2013-2018.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
